Assenagon Asset Management S.A. Has $355,000 Stake in Chimerix, Inc. (NASDAQ:CMRX)

Assenagon Asset Management S.A. lessened its stake in shares of Chimerix, Inc. (NASDAQ:CMRX) by 10.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 404,709 shares of the biopharmaceutical company’s stock after selling 49,759 shares during the period. Assenagon Asset Management S.A. owned 0.45% of Chimerix worth $355,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Koshinski Asset Management Inc. bought a new stake in Chimerix in the first quarter valued at $42,000. Vance Wealth Inc. acquired a new stake in shares of Chimerix in the 4th quarter valued at about $46,000. Marquette Asset Management LLC increased its position in Chimerix by 24.3% in the 1st quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock valued at $123,000 after buying an additional 22,709 shares in the last quarter. Pale Fire Capital SE raised its stake in Chimerix by 113.6% during the 4th quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 112,318 shares during the period. Finally, Vestal Point Capital LP bought a new position in Chimerix in the fourth quarter worth approximately $1,348,000. 45.42% of the stock is owned by institutional investors.

Chimerix Stock Down 2.0 %

CMRX stock opened at $0.98 on Friday. The stock’s 50 day moving average is $0.89 and its 200-day moving average is $0.97. Chimerix, Inc. has a twelve month low of $0.75 and a twelve month high of $1.30. The firm has a market capitalization of $87.84 million, a PE ratio of -1.05 and a beta of 1.20.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, meeting the consensus estimate of ($0.23). Chimerix had a negative return on equity of 41.32% and a negative net margin of 25,337.96%. The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $1.26 million. During the same period last year, the business earned ($0.21) EPS. On average, equities research analysts anticipate that Chimerix, Inc. will post -0.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on CMRX shares. StockNews.com upgraded Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday. Wedbush reaffirmed an “outperform” rating and issued a $6.00 price objective on shares of Chimerix in a research note on Tuesday, August 13th. Finally, HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Chimerix in a research report on Wednesday, August 14th.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.